top of page

Japan Lung Cancer Genomic Screening Project Expand To Seven Countries in Asia-Pacific Region

TAIPEI, TAIWAN, Jan.31, 2023- Lung cancer is a leading cause of death in both men and women in Asia. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer (NSCLC). The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells, are grouped together as NSCLC because their treatment and outlook are often similar.


Precision Medicine Asia (Premia), a cancer screening network, and the National Cancer Center Hospital East in Japan are building a lung cancer clinicopathological genomic database and screening infrastructure that spans seven countries in the Asia-Pacific region.


National Cancer Center Japan conducts a genomics screening project - LC-SCRUM-Japan collaborates with medical institutions and pharmaceutical manufacturers across the country. The organization has performed continuous screening of target genes for NSCLC in lung cancer patients since 2013 and has enrolled over 7,000 patients as of the end of January 2019.


On the other hand, Premia has already managed a clinical-genomic lung cancer database- LC-SCRUM-Asia and developed a genomic screening platform through the LC-SCRUM-AP platform. Patients from Thailand, Malaysia, Vietnam, Singapore, Indonesia, Australia, and Taiwan are able to enroll in clinical trials.


The goal is that academia and industry work together as a single organization to further the development of new drugs and diagnostics, with the aim of establishing personalized medicine for lung cancer. Currently, drugs targeting EGFR, ALK, ROS1, BRAF, NTRK, MET, RET, and KRAS gene mutations have already been approved in Japan, but may not be available in other countries in the Asia-Pacific region. Establishing a large-scale genomic database to identify and study patients with such mutations, some of which are rare, will help accelerate the development and commercialization of therapies targeting these mutations across multiple countries.


References:



About WASAI Technology Inc.

WASAI Technology's mission is to deliver acceleration technologies of High-Performance Data Analysis (HPDA) in future data centers for targeted vertical applications with massive volumes and high velocities of scientific data. To strengthen and advance scientific discovery and technological research via big data-intensive acceleration in high-performance computing, WASAI Technology aims to improve commercialization and commoditization of scientific and technological applications.

​​###

Comentarios


WASAI Tecnology Inc.

4F, No. 6, Zhiyuan 3rd Rd., Beitou Dist., Taipei 112025, Taiwan 

wasai@wasaitech.com

bottom of page